Friend D R
CIBUS Pharmaceutical Inc., California 94026-1226, USA.
Aliment Pharmacol Ther. 1998 Jul;12(7):591-603. doi: 10.1046/j.1365-2036.1998.00348.x.
Inflammatory bowel diseases are treated in some cases by local administration of anti-inflammatory drugs. Local delivery of drugs in the colon following oral administration may lead to improved efficacy/side-effect profiles and may improve patient compliance. This review covers a number of issues important in the design of oral delivery systems of glucocorticosteroids for local therapy of colonic inflammation. The choice of specific glucocorticosteroids is based on the drug's physicochemical and pharmacological properties. The conditions under which an orally administered glucocorticosteroid (or other drug) must be delivered to treat ulcerative colitis are also discussed. These conditions include variations in local pH, transit throughout the gastrointestinal tract, the potential role of gut microflora, and drug dissolution in both the healthy and diseased large intestine. The effective delivery of topically-active glucocorticosteroids in ulcerative colitis and Crohn's colitis patients is complex, but if successful could improve their usefulness.
在某些情况下，炎症性肠病通过局部施用抗炎药物进行治疗。口服给药后在结肠局部递送药物可能会提高疗效/副作用谱，并可能提高患者的依从性。本综述涵盖了在设计用于结肠炎症局部治疗的糖皮质激素口服给药系统中一些重要的问题。特定糖皮质激素的选择基于药物的物理化学和药理学特性。还讨论了口服糖皮质激素（或其他药物）必须递送以治疗溃疡性结肠炎的条件。这些条件包括局部pH值的变化、在整个胃肠道中的转运、肠道微生物群的潜在作用以及药物在健康和患病大肠中的溶解情况。在溃疡性结肠炎和克罗恩病性结肠炎患者中有效递送局部活性糖皮质激素是复杂的，但如果成功则可能提高其效用。
